PACTR202607754538830招募中3 期
Clinical Evaluation of Glycerol-Preserved Human Amniotic Membrane Versus Nanocrystalline Silver Dressing (Acticoat®) in Partial-Thickness Burns: A Prospective Within-Patient Randomised Controlled Trial
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 12 Year(s)（—）
- 性别
- All
入选标准
- •Patients aged =8 years presenting within 72 hours of acute partial thickness burn injury.
- •If they had two anatomically comparable wound sites suitable for within-patient comparison (bilateral/symmetric burns, or a single wound of sufficient area for division into two equivalent halves).
- •Eligible sites included wounds (burns or donor sites) on the limbs, torso, face, hands, or perineum.
排除标准
- •Patients with physical and/or mental conditions that are not expected to comply with the investigation.
- •Participation in other clinical investigation(s) within 1 month prior to and at the start of the investigation.
- •Patients with poor prognosis or who are critically ill.
- •Patients with full thickness burns or infected wounds.
研究组 & 干预措施
;Glycerol preserved human amniotic membrane;Acticoat
干预措施: ;Glycerol preserved human amniotic membrane;Acticoat
研究者
相似试验
尚未招募
不适用
Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Patients With Ph+ CML-CP (CABL001I12202)Pediatric Patients With Ph+ CML-CPjRCT20312602653
已完成
4 期
Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.Healthy subjects2025-524871-22-00Pevisal Group Farmaceutici S.r.l.24
招募中
4 期
The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.Not applicable (submitted trial is a bioavalability study in healthy participants).2025-524768-39-00Oxytone Bioscience B.V.4
招募中
1 期
Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid TumorsDose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.2023-509047-26-00Amgen Inc.135
招募中
1 期
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancersAdvanced solid tumors (cutaneous melanoma, mucosal melanoma, cutaneous squamous cell carcinoma, Merkel cell carcinoma, or basal cell carcinoma)2025-522402-21-00Kupando GmbH21